Schmidt, Wolfgang A.
Czihal, Michael
Gernert, Michael
Hartung, Wolfgang
Hellmich, Bernhard
Ohrndorf, Sarah
Riemekasten, Gabriela
Schäfer, Valentin S.
Strunk, Johannes
Venhoff, Nils
Article History
Accepted: 23 May 2024
First Online: 4 June 2024
Declarations
:
: The idea for drafting these recommendations originated in an expert panel initiated by Novartis Pharma GmbH, with 8 of 10 authors participating (all except VSS and WH). All subsequent activities for developing the recommendations were conducted independently of Novartis. W.A. Schmidt: <i>Speaker </i>for Abbvie, Amgen, Bristol Myers Squibb, Chugai, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Roche, UCB; <i>Consultant </i>for Abbvie, Amgen, Fresenius Kabi, GlaxoSmithKline, Novartis, Sanofi; <i>Research support </i>as principal investigator from Abbvie, GlaxoSmithKline, Novartis, Sanofi; <i>Member of recommendation initiatives </i>of EULAR (Imaging in rheumatoide arthritis, Management of PMR (EULAR/ACR), conducting of ultrasound courses, ultrasound synovitis scoring, management of large vessel vasculitides, imaging in large vessel vasculitis 2018 and 2023, publication von research on ultrasound, imaging in crystal arthropathies); of the British Society for Rheumatology (diagnosis and management of GCA), of AWMF (management of large vessel vasculitis, management of gout) and the International GCA/PMR Study Group (recommendations for early referral of individuals with suspected PMR). M. Czihal: <i>Speaker </i>for Bayer, Bristol Myers Squibb, Lilly, Leo Pharma, MSD Sharp & Dohme, Novartis, Roche, UCB; <i>Consultant</i> for Novartis, Roche. M. Gernert: <i>Speaker</i> for Abbvie, Lilly, Janssen, Novartis; <i>Consultant</i> for Amgen, Astrazeneca, Novartis, Takeda; <i>Congress sponsoring </i>from Abbvie, Lilly, Hexal, Janssen, Pfizer, UCB. W. Hartung: <i>Speaker</i> for Abbvie, Amgen, Bristol Myers Squibb, Chugai, Novartis; Alpinion; Canon HealthCare; <i>Board Member </i>of DEGUM. B. Hellmich: <i>Speaker </i>for Abbvie, AstraZeneca, BMS, GSK, Janssen, Novartis, Orgentec, Pfizer, Roche, Vifor; <i>Beraterhonorare </i>für Abbvie, BMS, InflaRx, GSK, Novartis, Roche, Vifor; <i>Member of recommendation initiatives: </i>The author was convenor of the EULAR Recommendations 2018 and the AWMF guidelines on management of large vessel vasculitis. S. Ohrndorf: <i>Speaker </i>for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb (BMS), Galapagos (Alfasigma), Janssen, Mylan, Novartis, UCB; <i>Consultant </i>for Amgen, Janssen, Novartis; <i>Research support</i> as Principal Investigator for Novartis. G. Riemekasten: <i>Consultant </i>for Novartis. V. Schäfer: <i>Speaker </i>for AbbVie, Novartis, BMS, Chugai, Celgene, Medac, Sanofi, Lilly, Hexal, Pfizer, Janssen, Roche, Schire, Onkowissen, Royal College London, Boehringer-Ingelheim, UCB Fresenius, Alexion; <i>Consultant </i>for Novartis, Chugai, AbbVie, Celgene, Sanofi, Lilly, Hexal, Pfizer, Amgen, BMS, Roche, Gilead, Medac, Boehringer-Ingelheim, Alexion; <i>Research support </i>from Novartis, Hexal, Lilly, Roche, Celgene, Universität Bonn, Boehringer-Ingelheim, Butterfly IQ, MEDAC, Alexion, DGRh. J. Strunk: <i>Speaker and Consultant</i> for AbbVie, Amgen, Chugai, BMS, Boehringer, GSK, Galapagos, Janssen-Cilag, Medac, Novartis, Pfizer, Roche, Sanofi, UCB. N. Venhoff: <i>Speaker</i> for AbbVie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Celgene, GSK, Novartis, Pfizer, Janssen, Roche, UCB, Vifor. <i>Consultant</i> for AbbVie, AstraZeneca, Boehringer-Ingelheim, GSK, Novartis, Pfizer, Janssen, Roche, UCB, Vifor. <i>Research support</i> from AbbVie, Medac, Novartis, Pfizer. <i>Member of recommendation initiative </i>of AWMF for management of large vessel vasculitis.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.
: The supplement containing this article is not sponsored by industry.